Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis, Inc. develops and commercializes medical technology for patients with cardiorenal conditions, including Aquadex SmartFlow ultrafiltration therapy for fluid removal in fluid overload. Company news commonly covers financial results, Aquadex software and product updates, patent activity for catheter technology, clinical case studies in pediatric and heart-failure care, medical-meeting participation, commercial territory expansion, and hospital-support initiatives.
Nuwellis (Nasdaq: NUWE) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,678,592 for the company’s Dual Lumen Catheter, a peripheral dual-lumen catheter intended for extracorporeal therapies such as ultrafiltration, dialysis, and continuous renal replacement therapy (CRRT). The patent was issued on July 14, 2026.
According to Nuwellis, the design uses a reinforcing stainless-steel coil to help prevent catheter collapse under negative pressure from blood pumps while allowing clinicians to trim the catheter to a patient-specific length without compromising structural integrity. The company states that this may improve blood flow, support longer filter life, and provide greater flexibility across adult and pediatric patient populations, further expanding its intellectual property portfolio in cardiorenal fluid management.
Nuwellis (Nasdaq: NUWE) will showcase its Aquadex SmartFlow therapy at the KidneyBee Summit 2026, held July 14-16, 2026 at Children's Hospital Colorado in Aurora. The company plans to engage pediatric nephrology and critical care clinicians on precise fluid management and ultrafiltration in children with acute kidney injury, cardiorenal conditions, and fluid overload.
Nuwellis (Nasdaq: NUWE) marks five years of supporting the Pediatric Cardiac Critical Care Consortium (PC4) annual conference, which focuses on care for children with critical and congenital cardiovascular disease.
The company backs clinician education on fluid management and use of its Aquadex SmartFlow ultrafiltration system in high-acuity pediatric and cardiac ICUs.
Nuwellis (Nasdaq: NUWE) announced installation of three Aquadex SmartFlow systems at a leading Michigan pediatric hospital, marking its first pediatric program in the state. The placement expands its pediatric critical care presence and supports development of clinical protocols and workflows for fluid management in children.
The Aquadex SmartFlow system provides ultrafiltration therapy for adult and pediatric patients ≥20 kg with fluid overload unresponsive to diuretics. Nuwellis also recently held an FDA pre-submission meeting on a proposed label expansion to include pediatric patients ≥5 kg.
Nuwellis (Nasdaq: NUWE)/b) shared a CEO transition and strategic update. Effective June 30, 2026, Mike McCormick becomes CEO while John Erb remains Chairman. In Q1 2026, revenue grew and gross margin reached 70.1%, a 14-point improvement.
About 75% of revenue comes from pediatric and critical care. Priorities include expanding Aquadex pediatric indications down to 5 kg, integrating the acquired Rendiatech kidney monitoring technology, strengthening capital, reducing cash burn, and targeting consistent double-digit revenue growth and continued margin expansion.
Nuwellis (Nasdaq: NUWE) supported the 4th University of Minnesota Critical Care Cardiology Education Summit by providing hands-on training with its Aquadex SmartFlow ultrafiltration system.
More than 280 physicians, including fellows and intensivists, received practical Aquadex training focused on fluid management in critically ill cardiac patients.
Nuwellis (Nasdaq: NUWE) appointed Mike McCormick as Chief Executive Officer, effective June 30, 2026. Current President, CEO, and Chairman John Erb will step down from executive duties and remain Chairman of the Board.
McCormick has over 30 years of medical technology leadership and previously served as a Nuwellis Board member.
Nuwellis (Nasdaq: NUWE) announced an expanded collaboration with a major South Carolina healthcare system to install new Aquadex SmartFlow devices at one of its children’s hospitals and upgrade devices at two existing sites. Aquadex provides precise ultrafiltration for adult and pediatric patients ≥20 kg with fluid overload.
Nuwellis recently held a pre-submission meeting with the FDA to discuss expanding Aquadex labeling to patients weighing ≥5 kg and expects to submit by the end of 2026.
Nuwellis (Nasdaq: NUWE) closed a registered public offering generating approximately $6.0 million in gross proceeds. The deal includes 1,903,338 common shares, 18,096,662 pre-funded warrants, and accompanying Series C (up to 60,000,000 shares) and Series D (up to 20,000,000 shares) warrants.
Common shares plus warrants were priced at $0.30; pre-funded warrants plus warrants at $0.2999. The SEC declared the related Form S-1 registration statements effective in early June 2026.
Nuwellis (Nasdaq: NUWE) priced a public offering of 20,000,000 shares of common stock (or pre-funded warrants) with accompanying warrants for expected gross proceeds of about $6 million at $0.30 per share and accompanying warrants.
The deal includes Series C and Series D warrants, each with a $0.30 exercise price and five-year term after required stockholder approval and a reverse stock split. The offering includes up to 60,000,000 Series C warrants and 20,000,000 Series D warrants. In a concurrent private placement, Nuwellis agreed to reprice certain existing warrants to a $0.30 exercise price, subject to stockholder approval.